Please select the option that best describes you:
Are there instances when you consider rituximab first line in a patient with class V LN?
Do you only reserve this for refractory cases?
Answer from: at Community Practice
No, I would not. I agree with the KDIGO and ACR lupus nephritis guidelines, which state that rituximab should be reserved for refractory cases and cases where the patient is intolerant of therapies that have stronger efficacy evidence (e.g., calcineurin inhibitors, cyclophosphamide, and mycophenolat...
Sign in or Register to read more